Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Archives of Medical Science : AMS|October 12, 2012
β-Globin chain abnormalities with coexisting α-thalassemia mutationsBirol Guvenc, Abdullah Canataroglu, Cagatay Unsal, et al.
Archives of Medical Science : AMS|August 2, 2012
β-Thalassemia mutations and hemoglobinopathies in Adana, Turkey: results from a single center studyBirol Guvenc, Abdullah Canataroglu, Cagatay Unsal, et al.
Indian Journal of Hematology & Blood Transfusion : an Official Journal of Indian Society of Hematology and Blood Transfusion|May 2, 2022
The Clinical Efficacy of Epoetin Alfa and Darbepoetin Alfa in Patients with Low-Risk or Intermediate-1-Risk Myelodysplastic Syndrome: Retrospective Multi-center Real-Life StudyMuzeyyen Aslaner Ak, Birsen Sahip, Ayfer Geduk, et al.
Mediterranean Journal of Hematology and Infectious Diseases|November 25, 2022
Impact of COVID-19 on Outcomes of Patients with Hematologic Malignancies: A Multicenter, Retrospective StudyIbrahim Halil Acar, Sebnem Izmir Guner, Muzeyyen Aslaner Ak, et al.
International Journal of Hematologic Oncology|June 6, 2022
The effect of comorbidities on the choice of tyrosine kinase inhibitors in patients with chronic myeloid leukemiaGuray Saydam, Ridvan Ali, Ahmet Muzaffer Demir, et al.
Expert Opinion on Pharmacotherapy|August 9, 2016
Outcomes with frontline nilotinib treatment in Turkish patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phaseGuray Saydam, Ibrahim Celalettin Haznedaroglu, Leylagul Kaynar, et al.
Hematology (Amsterdam, Netherlands)|July 13, 2018
Frontline nilotinib treatment in Turkish patients with Philadelphia chromosome-positive chronic Myeloid Leukemia in chronic phase: updated results with 2 years of follow-upGuray Saydam, Ibrahim Celalettin Haznedaroglu, Leylagul Kaynar, et al.
Hematology (Amsterdam, Netherlands)|March 1, 2018
Outcomes with frontline nilotinib treatment in Turkish patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phaseGuray Saydam, Ibrahim C Haznedaroglu, Leylagul Kaynar, et al.
Medicina (Kaunas, Lithuania)|October 26, 2024
Multicentral Retrospective Analysis of Venetoclax-Based Treatments in AML and MDS: A Real-World Study by the Turkish Hematology Network GroupIbrahim Halil Acar, Muzeyyen Aslaner Ak, Gulsah Akyol, et al.
Leukemia & Lymphoma|February 11, 2022
Real-world treatment patterns and clinical outcomes in patients with AML unfit for first-line intensive chemotherapy<sup></sup>Toshihiro Miyamoto, David Sanford, Ciprian Tomuleasa, et al.
Pageof 3